港股异动 | 三生制药(01530)涨超3% 抗VEGF/PD-1双特异性抗体获国家药监局突破性疗法认定

智通财经2025-04-22

智通财经APP获悉，三生制药(01530)涨超3%，截至发稿，涨2.84%，报12.3港元，成交额1.24亿港元。消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体(研发代码：707注射液)于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。据介绍，707注射液是三生制药基于CLF2专利平台自主...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529436787?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-22 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529436787","market":"sh","top_or_hot":-1,"title":"港股异动 | 三生制药(01530)涨超3% 抗VEGF/PD-1双特异性抗体获国家药监局突破性疗法认定","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，三生制药(01530)涨超3%，截至发稿，涨2.84%，报12.3港元，成交额1.24亿港元。消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体(研发代码：707注射液)于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。据介绍，707注射液是三生制药基于CLF2专利平台自主...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1282033.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 三生制药(01530)涨超3% 抗VEGF/PD-1双特异性抗体获国家药监局突破性疗法认定</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 三生制药(01530)涨超3% 抗VEGF/PD-1双特异性抗体获国家药监局突破性疗法认定\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-22 09:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1282033.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，三生制药(01530)涨超3%，截至发稿，涨2.84%，报12.3港元，成交额1.24亿港元。消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体(研发代码：707注射液)于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。据介绍，707注射液是三生制药基于CLF2专利平台自主...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1282033.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PD","symbol_name":"PagerDuty, Inc.","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1282033.html","article_id":"2529436787","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529436787","pubTimestamp":1745286407,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。据介绍，707注射液是三生制药基于CLF2专利平台自主开发的靶向VEGF/PD-1双特异性抗体，目前正于中国开展多项临床研究，其中一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌已获国家药监局药品审评中心批准开展III期临床研究。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PD":"PagerDuty, Inc.","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK1583":"高瓴概念","01530":"三生制药","BK1161":"生物科技","BK1593":"医美概念股","BK4023":"应用软件","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"Hong Kong stock changes 3SBio (01530) rose more than 3%, anti-VEGF/PD-1 bispecific antibody was recognized as a breakthrough therapy by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"01530":1},"content_text":"智通财经APP获悉，三生制药(01530)涨超3%，截至发稿，涨2.84%，报12.3港元，成交额1.24亿港元。消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体(研发代码：707注射液)于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。据介绍，707注射液是三生制药基于CLF2专利平台自主开发的靶向VEGF/PD-1双特异性抗体，目前正于中国开展多项临床研究，其中一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌已获国家药监局药品审评中心(CDE)批准开展III期临床研究。此外，707注射液正于国内开展联合化疗一线治疗晚期非小细胞肺癌、转移性结直肠癌及晚期妇科肿瘤等多项II期研究。707注射液的新药临床试验申请亦获得美国食品药品监督管理局的批准。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529436787","isCrawlerRequest":true}